Wyeth Heads To Court Again To Protect Effexor

By Shannon Henson

Law360, New York (July 06, 2009, 12:00 AM ET) -- In the latest chapter in its long-running fight to block generic competition for the popular antidepressant Effexor XR, Wyeth has slapped Orchid Chemicals & Pharmaceuticals Ltd. and subsidiary Orgenus Pharma Inc. with a patent infringement lawsuit.

The suit, filed Thursday in the U.S. District Court for the District of New Jersey, was triggered by Orchid's abbreviated new drug application filing with the U.S. Food and Drug Administration for the manufacture, use and sale of venlafaxine HCl extended release capsules in 37.5 mg, 75 mg and 150...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles